Item 7.01 Regulation FD Disclosure

On January 9, 2020, Ultragenyx Pharmaceutical Inc. (the "Company") posted a presentation (the "Presentation") to its website at www.ultragenyx.com in the "Events and Presentations" subsection of the "Investors" tab.

The information set forth under Item 7.01 and in the Presentation shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01 Other Events.

On January 9, 2020, the Company issued a press release (the "Press Release") announcing topline positive safety and efficacy data from the third dose cohort and longer-term data from the second dose cohort of its ongoing Phase 1/2 study of DTX301, an investigational adeno-associated virus gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency. A copy of the Press Release is filed as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits






(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated January 9, 2020.
104         The cover page from the Company's Current Report on Form 8-K dated
            January 9, 2020 formatted in Inline XBRL.






--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses